on's differentiated platform, an untapped clinical market, and the company's pharmaceutical business. The Cambridge, Mass.-based company offers the FoundationOne cancer panel for solid tumors and the FoundationOne Heme for blood-based cancers. Together, the tests represent "the most comprehensive set of gene

er last year and a 26% increase from the 4,702 tests reported in this year's first quarter. This number includes 4,960 FoundationOne* tests and 948 FoundationOne Heme tests. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatr